In focus
Latest feed
Roche's Remarkable Rally: Diving into H1 2026 Performance and the Market's Surprising Enthusiasm
Investor Optimism Fuels Roche's Ascent Amidst Nuanced H1 2026 Report
A New Dawn: Roche's Landmark Drug Redefines Hope for KRAS-Driven Lung Cancer Patients
A Renewed Sense of Hope: Roche's Ocrevus Continues to Impress in MS Care
